Relipulse Pharmaceuticals Private Limited
About Relipulse Pharmaceuticals Private Limited
Data last updated:
Relipulse Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the paper and paper products segment of the paper and packaging sector. It was incorporated on 10 August 2023.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U21001TS2023PTC175918.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Rekha Devi Upadhyay and Komal Upadhyay.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.44 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹72.6 Lakh (net margin 13.4%) and EBITDA of ₹84.1 Lakh (EBITDA margin 15.5%).
As per MCA filings, the company has open charges of ₹1.1 Cr on record.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressD No 3 – 5 – 592 2nd Floor, Sunder Sadan, Hyderabad, Telangana, India – 500029
- IndustryPaper, Paper & Paper Products, Manufacturing
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Relipulse Pharmaceuticals Private Limited
The main business activity of Relipulse Pharmaceuticals is trade. In detail, this covers retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Relipulse Pharmaceuticals Private Limited FY 2025 filings available
Relipulse Pharmaceuticals Private Limited reported revenue of ₹5.44 Cr (up 1204% YoY) for FY 2025.
Financial Statement Summary of Relipulse Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | •••• | •••• |
| Other Income | •••• | •••• |
| Total Revenue | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• |
| Employee Benefit Expense | •••• | •••• |
| Finance Costs | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• |
| Other Expenses | •••• | •••• |
| Total Expenses | •••• | •••• |
| EBITDA | ₹84.1 Lakh | •••• |
| Profit Before Tax | •••• | •••• |
| Tax Expense | •••• | •••• |
| Net Profit (PAT) | ₹72.6 Lakh | •••• |
| Balance Sheet | ||
| Share Capital | •••• | •••• |
| Reserves and Surplus | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• |
| Long-term Borrowings | •••• | •••• |
| Short-term Borrowings | •••• | •••• |
| Trade Payables | •••• | •••• |
| Total Liabilities | •••• | •••• |
| Fixed Assets | •••• | •••• |
| Investments | •••• | •••• |
| Inventories | •••• | •••• |
| Trade Receivables | •••• | •••• |
| Cash and Bank Balance | •••• | •••• |
| Total Assets | •••• | •••• |
Financial Ratios of Relipulse Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 15.5% | •••• |
| Net Profit Margin | 13.4% | •••• |
| Return on Equity (ROE) | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• |
| Liquidity and Debt | ||
| Current Ratio | •••• | •••• |
| Quick Ratio | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• |
| Efficiency and Growth | ||
| Asset Turnover | •••• | •••• |
| Receivable Days | •••• | •••• |
| Payable Days | •••• | •••• |
| Inventory Days | •••• | •••• |
| Revenue Growth | •••• | •••• |
| Net Profit Growth | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Relipulse Pharmaceuticals are in the company report.
Financial statements from FY 2024
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Relipulse Pharmaceuticals Private Limited
Relipulse Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rekha Devi Upadhyay | Director | 10 Aug 2023 | 3 Years 2 Months | Current |
| Komal Upadhyay | Director | 10 Aug 2023 | 3 Years 2 Months | Current |
Peer Comparison of Relipulse Pharmaceuticals Private Limited
Relipulse Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| DB Wellness Private Limited | ₹5.46 Cr (FY 2025) | •••• | •••• | -81.0% | •••• | Nadia, West Bengal, India |
| Hero Enterprises Pvt Ltd | ₹5.46 Cr (FY 2024) | •••• | •••• | 35.0% | •••• | Punjab, India |
| A B S Remedies Private Limited | ₹5.45 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | New Delhi, Delhi, India |
| Suntril Pharmaceuticals Private Limited | ₹5.45 Cr (FY 2024) | •••• | •••• | 19.0% | •••• | Chandigarh, India |
| Aripolis Biotech Private Limited | ₹5.45 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Ludhiana, Punjab, India |
| Relipulse Pharmaceuticals Private Limited this company | ₹5.44 Cr (FY 2025) | •••• | •••• | 1204.0% | •••• | Hyderabad, Telangana, India |
| Care Benzorganics Private Limited | ₹5.44 Cr (FY 2024) | •••• | •••• | -27.0% | •••• | Hyderabad, Telangana, India |
| Rako Agrochem Private Limited | ₹5.43 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Lucknow, Uttar Pradesh, India |
| Ramose Laboratories Private Limited | ₹5.43 Cr (FY 2024) | •••• | •••• | -4.0% | •••• | Delhi, India |
| Grevis Pharmaceuticals Private Limited | ₹5.43 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | Gurgaon, Haryana, India |
| Shinto Organics Private Limited | ₹5.43 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Chandigarh, India |
Peers are the five companies nearest above and the five nearest below Relipulse Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Charges & Borrowings of Relipulse Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Dec 2025 | Hdfc Bank Limited | ₹1.1 Cr | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Relipulse Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Relipulse Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Relipulse Pharmaceuticals Private Limited
Relipulse Pharmaceuticals Private Limited has 2 board changes on record since 2023: 2 appointments. The latest: Komal Upadhyay was appointed as Director on 10 Aug 2023.
Credit Ratings, Litigation & Regulatory Alerts for Relipulse Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Relipulse Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Relipulse Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Relipulse Pharmaceuticals Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Relipulse Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Relipulse Pharmaceuticals Private Limited
Relipulse Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in paper and paper products, within the paper industry. It was incorporated on 10 August 2023 (3+ years old) and is registered under CIN U21001TS2023PTC175918.
Relipulse Pharmaceuticals reported revenue of ₹5.44 Cr for FY 2025 (up 1204% YoY).
Relipulse Pharmaceuticals has 2 current directors:
- Rekha Devi Upadhyay - Director
- Komal Upadhyay - Director
Relipulse Pharmaceuticals reported a net profit of ₹72.6 Lakh (net margin 13.4%) and EBITDA of ₹84.1 Lakh (EBITDA margin 15.5%) for FY 2025, as per its filed financial statements.
The CIN (Corporate Identification Number) of Relipulse Pharmaceuticals is U21001TS2023PTC175918. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Relipulse Pharmaceuticals was incorporated on 10 August 2023, making it 3+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Relipulse Pharmaceuticals by revenue are DB Wellness Private Limited, Hero Enterprises Pvt Ltd, A B S Remedies Private Limited, Suntril Pharmaceuticals Private Limited, Aripolis Biotech Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Komal Upadhyay was appointed as Director on 10 Aug 2023. Rekha Devi Upadhyay was appointed as Director on 10 Aug 2023.
The registered office of Relipulse Pharmaceuticals is at D No 3 – 5 – 592 2nd Floor, Sunder Sadan, Hyderabad, Telangana, India – 500029.
Relipulse Pharmaceuticals has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh.
Relipulse Pharmaceuticals operates in the paper industry, in the paper and paper products segment.